Patent · US Active

Compositions and methods for inhibition of the JAK pathway

US7834024B2 · kind B2 · utility

56Cited by

6References

6Claims

0Family size

Assignee

Rigel Pharmaceuticals, Inc. · US

Inventors

Hui Li · Santa Clara, US
Vanessa Taylor · San Francisco, US
Somasekhar Bhamidipati · Foster City, US
John Ramphal · Union City, US
Kin Tso · San Francisco, US
Avinder Sran · Fremont, US
Holger Keim · Irvine, US
Vadim Markovtsov · San Mateo, US
David Carroll · San Francisco, US
Sambaiah Thota · Fremont, US
Ankush Argade · Foster City, US
Jeffrey Clough · Redwood City, US
Rajinder Singh · Belmont, US
Robin Cooper · St. Augustine, US

Key dates

Filing date	Mar 21, 2008
Grant date	Nov 16, 2010
Priority date	—
Expiry date	Mar 21, 2028

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D498/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.